Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

(247,360,000) (230,836,000) ------------ ------------ Total stockholders' equity 901,000 15,595,000 ------- ---------- TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $23,127,000 $23,057,000 =========== ===========

    PEREGRINE PHARMACEUTICALS, INC.

    CONSOLIDATED STATEMENTS OF OPERATIONS
    FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2009


                                         2009           2008           2007
                                         ----           ----           ----

    REVENUES:
    Contract manufacturing revenue   $12,963,000     $5,897,000     $3,492,000
    Government contract revenue        5,013,000              -              -
    License revenue                      175,000        196,000        216,000
                                         -------        -------        -------

      Total revenues                  18,151,000      6,093,000      3,708,000

    COSTS AND EXPENSES:
    Cost of contract manufacturing     9,064,000      4,804,000      3,296,000
    Research and development          18,424,000     18,279,000     15,876,000
    Selling, general and
     administrative                    6,979,000      7,150,000      6,446,000
                                       ---------      ---------      ---------

      Total costs and expenses        34,467,000     30,233,000     25,618,000
                                      ----------     ----------     ----------

    LOSS FROM OPERATIONS             (16,316,000)   (24,140,000)  (21,910,000)

    OTHER INCOME (EXPENSE):
    Interest and other income            200,000        989,000      1,160,000
    Interest and other expense          (408,000)       (25,000) 
'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Alan Mozes HealthDay Reporter , ... of infectious diseases, one worrisome phenomenon is when an illness ... process -- known as zoonosis -- is not uncommon and ... that an animal-borne disease might make inroads into the human ... development -- and the culprits in this case were guinea ...
(Date:12/17/2014)... (HealthDay News) -- Poor students get more fruits and vegetables ... finds. But, the opposite is true for students from ... vegetables at school may give a healthy boost to poor ... what the family income level, students all ate a similar ... The study was published recently in the journal ...
(Date:12/17/2014)... Alan Mozes HealthDay Reporter ... party season fast approaching, a new study reveals that states ... have fewer drunk drivers on their roads. The finding ... are better able to deter inebriated revelers from getting behind ... laws are being passed regarding drinking and driving," said study ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, 2014 ... and work commitment is a big reason why, new research ... Dr. Mathias Basner, an assistant professor of sleep and chronobiology ... Medicine. A time-use survey of nearly 125,000 Americans, ages ... activity exchanged for sleep. Short sleepers -- those who slept ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Cancer researchers ... possible underlying genetic causes of deadly malignant pleural mesothelioma. ... research on their website. Click here to read ... University of Hawaii Cancer Center, and New York’s Langone ... malignant pleural mesothelioma patients in an effort to ...
Breaking Medicine News(10 mins):Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2
... Scientists know little about how the brain creates and ... obstacle in the effort to develop treatments for emotional ... is in its infancy," says Howard Hughes Medical Institute ... continue to take an enormous toll on human society." ...
... heart risk, leaked documents suggest , SATURDAY, Feb. 20 ... Avandia raises users, odds for heart attack and heart ... to confidential government reports. , The New York ... U.S. Food and Drug Administration that find that if ...
... ... it,s new shop in Beverly Hills, featuring old style barbering, straight razor shaves, in a ... ... today the official opening of its Beverly Hills store located at 9635 Brighton Way, Beverly ...
... ... chief loss mitigator for IndyMac Banks HELOC division, conducted a short sale continuing ... Honish is the first bank employee approved by any state to conduct a ... only course on the subject of short sales taught from this perspective. The ...
... ... ... , ... , ...
... ... ... ... , ...
Cached Medicine News:Health News:David Anderson to discuss what model organisms can teach us about emotion 2Health News:Remove Diabetes Drug Avandia From Market: FDA Reports 2Health News:Remove Diabetes Drug Avandia From Market: FDA Reports 3Health News:Remove Diabetes Drug Avandia From Market: FDA Reports 4Health News:The Classic Shave Company Announces the Opening of Beverly Hills Shop 2Health News:Former Bank Negotiator Turns On Bank and is Approved by the Department of Real Estate 2Health News:Former Bank Negotiator Turns On Bank and is Approved by the Department of Real Estate 3Health News:California Dental Association Foundation Expands Care to State's Underserved Communities 2Health News:California Dental Association Foundation Expands Care to State's Underserved Communities 3Health News:California Dental Association Foundation Expands Care to State's Underserved Communities 4Health News:California Dental Association Foundation Expands Care to State's Underserved Communities 5Health News:WebMD to Present at the Goldman Sachs Technology and Internet Conference 2010 2Health News:WebMD to Present at the Goldman Sachs Technology and Internet Conference 2010 3
(Date:12/15/2014)... Israel , Dec. 15, 2014  Immune Pharmaceuticals Inc. ... that its Board of Directors has elected Mr. Daniel Kazado ... who continues as Chief Executive Officer of Immune. Mr. Kazado ... 2013. Immune,s new Chairman, Mr. Daniel Kazado ... shareholders and to continue to support the strategic vision of ...
(Date:12/15/2014)... BRIDGEWATER, N.J. , Dec. 15, 2014 /PRNewswire/ ... (EURONEXT: SAN and NYSE: SNY) are collaborating with nationally-recognized ... Cholesterol Counts , an awareness program that will gauge ... the risks associated with high LDL-C (bad cholesterol).  American ... to take a brief poll and answer a ...
(Date:12/15/2014)... Investor-Edge has initiated coverage on the ... Lilly and Company (NYSE: LLY ), Nektar Therapeutics ... ), and Novartis AG (NYSE: NVS ). Free ... http://investor-edge.com/register . On Friday, December 12, 2014, the ... Industrial Average lost 1.79%, to finish the day at 17,280.83, ...
Breaking Medicine Technology:Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5
... 2012 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... devices worldwide, today announced updates on new product launches for ... in 2012. N ew product ... new products, exceeding its product development goals outlined at the ...
... CFN ) today announced preliminary second quarter results ... CEO Kieran T. Gallahue at the annual J.P. Morgan Healthcare ... its second fiscal quarter, ended Dec. 31, 2011, to be ... $141 million to $146 million. Excluding nonrecurring items, adjusted operating ...
Cached Medicine Technology:Mindray Medical Exceeds 2011 Product Development Targets and Announces Strong 2012 Pipeline 2Mindray Medical Exceeds 2011 Product Development Targets and Announces Strong 2012 Pipeline 3Mindray Medical Exceeds 2011 Product Development Targets and Announces Strong 2012 Pipeline 4CareFusion Announces Preliminary Second Quarter Results 2CareFusion Announces Preliminary Second Quarter Results 3CareFusion Announces Preliminary Second Quarter Results 4CareFusion Announces Preliminary Second Quarter Results 5CareFusion Announces Preliminary Second Quarter Results 6
Large solid mallet with patented Ortho-Grip® silicone rubber handle....
Straight chisel for scoring, cutting, scraping, cleaning and sculpting bone....
Custom-made chisels....
Lewin Bone Forceps, serrated and slightly curved. To hold, stabilize, rotate, reduce and,compress bone....
Medicine Products: